NextCure (NXTC) Investor Presentation - Slideshow

Pipeline and Programs - NC318 (targeting Siglec-15) Phase 1/2 topline data is expected in Q4 2019[6], with Phase 1 initiated in October 2018[23] - NC410 (LAIR-1) IND filing is expected in Q1 2020[6], designed to promote T cell function and dendritic cell activity[58] - Multiple discovery and research programs are underway, with the first IND filing anticipated in early 2021[20] - The FIND-IO platform aims for its first IND filing in late 2022[20] Financial and Partnerships - An oncology partnership with Eli Lilly includes $40 million upfront and equity[7] - NextCure has a strong balance sheet to deliver on objectives[7] NC318 Details - NC318 targets tumors and macrophages by blocking S15-induced immunosuppression[23] - Phase 1 trial of NC318 had 21 subjects dosed as of March 31, 2019, with the 4th dose cohort open[54] - In the NC318 Phase 1 trial, there was 1 confirmed partial response, 6 stable diseases, and 6 progressive diseases[55] - S15 and PD-L1 expression generally do not overlap in NSCLC tumors, suggesting NC318 as a potential treatment for PD-1/PD-L1 non-responders[34] NC410 Details - NC410 is a decoy human fusion protein targeting the TME, specifically Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1)[58] - NC410 is designed to prevent immune suppression caused by LAIR-1, promoting T cell function and dendritic cell activation[62, 63] FIND-IO Platform - The FIND-IO platform is a functional, integrated discovery engine for immuno-oncology[76] - Lilly–NextCure partnership to validate platform and approach includes $25 million upfront and $15 million equity investment[86]